CMOPF.US Cosmo Pharmaceuticals N.V

Healthcare Pharmaceuticals USA Stocks
71.59 USD
Close of Nov 13, 2026
59.02 163.16
Market cap
USD 1.23B
P/E
-
P/B
1.95x
ROE
-3.3%
Dividend yield
3.45%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is CMOPF.US undervalued?

Graham number

The Graham number of Cosmo Pharmaceuticals N.V cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cosmo Pharmaceuticals N.V fundamental analysis

No fundamental analysis for Cosmo Pharmaceuticals N.V yet.

Cosmo Pharmaceuticals N.V stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cosmo Pharmaceuticals N.V

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to…

Full company profile